Virtu Financial LLC raised its position in Sophiris Bio Inc (NASDAQ:SPHS) by 389.7% in the 4th quarter, HoldingsChannel reports. The fund owned 169,790 shares of the biopharmaceutical company’s stock after acquiring an additional 135,119 shares during the quarter. Virtu Financial LLC’s holdings in Sophiris Bio were worth $385,000 at the end of the most recent quarter.
Separately, Vanguard Group Inc. boosted its stake in shares of Sophiris Bio by 1.0% in the 2nd quarter. Vanguard Group Inc. now owns 731,437 shares of the biopharmaceutical company’s stock valued at $1,609,000 after buying an additional 7,600 shares during the period. 6.37% of the stock is owned by institutional investors.
Several equities analysts have recently issued reports on SPHS shares. Maxim Group set a $6.00 price objective on Sophiris Bio and gave the company a “buy” rating in a research note on Monday, December 11th. HC Wainwright set a $6.00 price objective on Sophiris Bio and gave the company a “buy” rating in a research note on Wednesday, January 17th. Finally, ValuEngine upgraded Sophiris Bio from a “strong sell” rating to a “sell” rating in a research note on Friday, December 15th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Sophiris Bio presently has an average rating of “Buy” and an average target price of $6.00.
Sophiris Bio Inc (NASDAQ SPHS) opened at $2.14 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 13.37 and a quick ratio of 13.37. The stock has a market capitalization of $65.64, a PE ratio of -16.46 and a beta of 1.87. Sophiris Bio Inc has a 52 week low of $1.80 and a 52 week high of $2.95.
WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/10/virtu-financial-llc-grows-holdings-in-sophiris-bio-inc-sphs.html.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Want to see what other hedge funds are holding SPHS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sophiris Bio Inc (NASDAQ:SPHS).
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.